Latest Breaking News On - Solid tumor targeting - Page 1 : comparemela.com

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year's Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster.

San diegoUnited statesTubuli tubutecanJonas helma smetsTubutecan adcsProduct servicePresents preclinical dataSolid tumor targetingSuperior efficacy profileWide therapeutic windowAnnual meetingAmerican associationCancer researchChief scientific officerFc silenced igg